Literature DB >> 23844703

The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Zhaohua Lu1, Michael J Rynkiewicz, Chiou-Ying Yang, Guillermo Madico, Hillary M Perkins, Qi Wang, Catherine E Costello, Joseph Zaia, Barbara A Seaton, Jacqueline Sharon.   

Abstract

We have previously described two types of protective B-cell epitopes in the O-antigen (OAg) of the Gram-negative bacterium Francisella tularensis: repeating internal epitopes targeted by the vast majority of anti-OAg monoclonal antibodies (mAbs), and a non-overlapping epitope at the non-reducing end targeted by the previously unique IgG2a mAb FB11. We have now generated and characterized three mAbs specific for the non-reducing end of F. tularensis OAg, partially encoded by the same variable region germline genes, indicating that they target the same epitope. Like FB11, the new mAbs, Ab63 (IgG3), N213 (IgG3) and N62 (IgG2b), had higher antigen-binding bivalent avidity than internally binding anti-OAg mAbs, and an oligosaccharide containing a single OAg repeat was sufficient for optimal inhibition of their antigen-binding. The X-ray crystal structure of N62 Fab showed that the antigen-binding site is lined mainly by aromatic amino acids that form a small cavity, which can accommodate no more than one and a third sugar residues, indicating that N62 binds mainly to the terminal Qui4NFm residue at the nonreducing end of OAg. In efficacy studies with mice infected intranasally with the highly virulent F. tularensis strain SchuS4, N62, N213 and Ab63 prolonged survival and reduced blood bacterial burden. These results yield insights into how antibodies to non-reducing ends of microbial polysaccharides can contribute to immune protection despite the smaller size of their target epitopes compared with antibodies to internal polysaccharide regions.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  bacteria/bacterial immunity; endotoxin/lipopolysaccharide; epitopes; immunoglobulins; vaccines

Mesh:

Substances:

Year:  2013        PMID: 23844703      PMCID: PMC3800442          DOI: 10.1111/imm.12150

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  61 in total

Review 1.  Recognition of a carbohydrate antigenic determinant of Salmonella by an antibody.

Authors:  M Cygler; S Wu; A Zdanov; D R Bundle; D R Rose
Journal:  Biochem Soc Trans       Date:  1993-05       Impact factor: 5.407

2.  Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution.

Authors:  A Zdanov; Y Li; D R Bundle; S J Deng; C R MacKenzie; S A Narang; N M Young; M Cygler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

3.  Model-building study of the combining sites of two antibodies to alpha (1----6)dextran.

Authors:  E A Padlan; E A Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

4.  Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells.

Authors:  T R Rhinehart-Jones; A H Fortier; K L Elkins
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

5.  Production and characterization of monoclonal antibodies directed against the lipopolysaccharide of Francisella tularensis.

Authors:  M J Fulop; T Webber; R J Manchee; D C Kelly
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

6.  Structure of the O-antigen of Francisella tularensis strain 15.

Authors:  E V Vinogradov; A S Shashkov; Y A Knirel; N K Kochetkov; N V Tochtamysheva; S F Averin; O V Goncharova; V S Khlebnikov
Journal:  Carbohydr Res       Date:  1991-07-30       Impact factor: 2.104

7.  Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice.

Authors:  A Rashid; H Auchincloss; J Sharon
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

8.  Live vaccine strain of Francisella tularensis: infection and immunity in mice.

Authors:  A H Fortier; M V Slayter; R Ziemba; M S Meltzer; C A Nacy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

9.  Immunotherapy of tularemia: characterization of a monoclonal antibody reactive with Francisella tularensis.

Authors:  R B Narayanan; J J Drabick; J C Williams; A H Fortier; M S Meltzer; J C Sadoff; C R Bolt; C A Nacy
Journal:  J Leukoc Biol       Date:  1993-01       Impact factor: 4.962

10.  Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.

Authors:  J L Dangl; T G Wensel; S L Morrison; L Stryer; L A Herzenberg; V T Oi
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  10 in total

Review 1.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

2.  Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.

Authors:  Zhaohua Lu; Hillary M Perkins; Jacqueline Sharon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

3.  Specificity of furanoside-protein recognition through antibody engineering and molecular modeling.

Authors:  Parnian Lak; Spandana Makeneni; Robert J Woods; Todd L Lowary
Journal:  Chemistry       Date:  2014-11-20       Impact factor: 5.236

4.  The Tip of Brucella O-Polysaccharide Is a Potent Epitope in Response to Brucellosis Infection and Enables Short Synthetic Antigens to Be Superior Diagnostic Reagents.

Authors:  Lucy Duncombe; Laurence Howells; Anna Haughey; Andrew V Taylor; Daryan Kaveh; Sevil Erdenliğ Gϋrbilek; Anne Dell; Paul G Hitchen; Stuart M Haslam; Satadru Sekhar Mandal; N Vijaya Ganesh; David R Bundle; John McGiven
Journal:  Microorganisms       Date:  2022-03-25

5.  Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.

Authors:  Zhaohua Lu; Michael J Rynkiewicz; Chiou-Ying Yang; Guillermo Madico; Hillary M Perkins; Marly I Roche; Barbara A Seaton; Jacqueline Sharon
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08

6.  Novel Solutions for Vaccines and Diagnostics To Combat Brucellosis.

Authors:  Satadru Sekhar Mandal; Lucy Duncombe; N Vijaya Ganesh; Susmita Sarkar; Laurence Howells; Philip J Hogarth; David R Bundle; John McGiven
Journal:  ACS Cent Sci       Date:  2017-03-03       Impact factor: 14.553

Review 7.  The role of phage display in therapeutic antibody discovery.

Authors:  Conrad E Z Chan; Angeline P C Lim; Paul A MacAry; Brendon J Hanson
Journal:  Int Immunol       Date:  2014-08-18       Impact factor: 4.823

8.  Impact of Immunoglobulin Isotype and Epitope on the Functional Properties of Vibrio cholerae O-Specific Polysaccharide-Specific Monoclonal Antibodies.

Authors:  Robert C Kauffman; Oluwaseyi Adekunle; Hanyi Yu; Alice Cho; Lindsay E Nyhoff; Meagan Kelly; Jason B Harris; Taufiqur Rahman Bhuiyan; Firdausi Qadri; Stephen B Calderwood; Richelle C Charles; Edward T Ryan; Jun Kong; Jens Wrammert
Journal:  mBio       Date:  2021-04-20       Impact factor: 7.867

9.  Protection against Experimental Melioidosis with a Synthetic manno-Heptopyranose Hexasaccharide Glycoconjugate.

Authors:  Andrew E Scott; William J Christ; Alison J George; Margaret G M Stokes; Gregory J S Lohman; Yuhong Guo; Matthew Jones; Richard W Titball; Timothy P Atkins; A Stewart Campbell; Joann L Prior
Journal:  Bioconjug Chem       Date:  2016-05-17       Impact factor: 4.774

10.  Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans.

Authors:  David R Bundle; John McGiven
Journal:  Acc Chem Res       Date:  2017-12-08       Impact factor: 22.384

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.